Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting

BACKGROUND: A regimen of dual (DAT) vs. triple (TAT) antithrombotic therapy reduces bleeding in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, recent evidence suggests that DAT may be associated with an increased ischemic risk. This raises the qu...

Descripción completa

Detalles Bibliográficos

Autores principales:	Riesinger, Lisa, Strobl, Claudia, Leistner, David M., Gori, Tommaso, Akin, Ibrahim, Mehr, Michael, Kellnar, Antonia, Mahabadi, Amir A., Bogossian, Harilaos, Block, Michael, Edelmann, Frank, Sarafoff, Nikolaus, Sibbing, Dirk, Ince, Hüseyin, Rassaf, Tienush, Mansmann, Ulrich, Mehilli, Julinda, Kääb, Stefan, Hausleiter, Jörg, Massberg, Steffen, Wakili, Reza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256176/ https://www.ncbi.nlm.nih.gov/pubmed/34258380 http://dx.doi.org/10.1016/j.ijcha.2021.100810